Molecular Microbiology (Virology)
Institute of Medical Microbiology and Hygiene
University Regensburg


We aim to improve the quality of life and health across the globe by developing new vaccines, from the bench to the clinic.

With our vaccine research, we aim to contribute to the fight against viruses for which no vaccines exist so far (e.g., HIV), which are endemic in lower-income countries with high fatality rates (e.g., Ebola, Marburg, Lassa, Crimean-Congo haemorrhagic fever virus), which have the potential to cause the next pandemic (e.g., influenza and coronaviruses), and which are associated with malignancies (e.g., HPV) or severe clinical manifestations in certain risk groups (e.g., CMV).

In addition to our research, we strive to educate our students through an attractive range of courses, bachelor’s, master’s, and doctoral theses, and to prepare them for the primary labor market. Where appropriate, we also endeavor to translate our research results into commercial products and services.


Our vaccine efforts are based on:

  • Epidemiological data generation and analysis (viral, immunological, B and T cells)
  • A deep understanding of viral replication and pathogenesis
  • Cutting-edge protein design and manufacturing capabilities
  • Platform technologies for optimal delivery of protein-based antigens, both nonviral and viral
  • Testing in non-human primates (in cooperation with partners)
  • Phase 1 to 2b clinical trials (in cooperation with clinical partners)